Tibra Equities Europe’s Fate Therapeutics FATE Stock Holding History

Tibra Equities Europe’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,900	Closed	-$221K	–	260
2019 Q2	$221K	Buy	+10,900	New	+$196K	0.02%	225

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

Tibra Equities Europe's FATE Position: Q3 2019 in Review

Tibra Equities Europe sold out of Fate Therapeutics (FATE) in Q3 2019, closing a stake of 10,900 shares — an estimated $221K sold.

Tibra Equities Europe first reported a position in FATE in Q2 2019 and held it in 1 quarter. The position peaked at $221K in Q2 2019. 149 funds tracked by Wall St. Rank hold FATE as of Q3 2019.

Tibra Equities Europe reported no remaining Fate Therapeutics position as of Q3 2019 after selling out during the quarter.
Tibra Equities Europe sold 10,900 Fate Therapeutics shares in Q3 2019, an estimated $221K.
Tibra Equities Europe first reported a position in Fate Therapeutics in Q2 2019 and held it in 1 quarter.
Tibra Equities Europe's Fate Therapeutics position peaked at $221K in Q2 2019.
149 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2019.

Based on Tibra Equities Europe's 13F filing for Q3 2019, filed 4 Nov 2019.